Enhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptamer.
Humans
Doxorubicin
/ pharmacology
Mucin-1
/ metabolism
Liposomes
/ chemistry
Cisplatin
/ pharmacology
Aptamers, Nucleotide
/ chemistry
Cell Survival
/ drug effects
Apoptosis
/ drug effects
Cell Line, Tumor
HeLa Cells
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Antineoplastic Agents
/ pharmacology
Drug Compounding
/ methods
MUC‐1
cisplatin
combine drug
doxorubicin
niosome
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
10
07
2024
received:
10
06
2024
accepted:
24
07
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
9
8
2024
Statut:
ppublish
Résumé
Cancer remains a formidable global health challenge, currently affecting nearly 20 million individuals worldwide. Due to the absence of universally effective treatments, ongoing research explores diverse strategies to combat this disease. Recent efforts have concentrated on developing combined drug regimens and targeted therapeutic approaches. This study aimed to investigate the anticancer efficacy of a conjugated drug system, consisting of doxorubicin and cisplatin (Dox-Cis), encapsulated within niosomes and modified with MUC-1 aptamers to enhance biocompatibility and target specific cancer cells. The chemical structure of the Dox-Cis conjugate was characterized using Fourier Transform Infrared Spectroscopy (FTIR) and Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-Q-TOF/MS). The zeta potential and morphological parameters of the niosomal vesicles were determined through Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). In vitro assessments of cell viability and apoptosis were conducted on MUC-1 positive HeLa cells and MUC-1 negative U87 cells. The findings confirmed the successful conjugation of Dox and Cis within the niosomes. The Nio/Dox-Cis/MUC-1 formulation demonstrated enhanced efficacy compared to the individual drugs and their unencapsulated combination in both cell lines. Notably, the Nio/Dox-Cis/MUC-1 formulation exhibited greater effectiveness on HeLa cells (38.503 ± 1.407) than on U87 cells (46.653 ± 1.297). The study underscores the potential of the Dox-Cis conjugate as a promising strategy for cancer treatment, particularly through platforms that facilitate targeted drug delivery to cancer cells. This targeted approach could lead to more effective and personalized cancer therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer remains a formidable global health challenge, currently affecting nearly 20 million individuals worldwide. Due to the absence of universally effective treatments, ongoing research explores diverse strategies to combat this disease. Recent efforts have concentrated on developing combined drug regimens and targeted therapeutic approaches.
OBJECTIVE
OBJECTIVE
This study aimed to investigate the anticancer efficacy of a conjugated drug system, consisting of doxorubicin and cisplatin (Dox-Cis), encapsulated within niosomes and modified with MUC-1 aptamers to enhance biocompatibility and target specific cancer cells.
METHODS
METHODS
The chemical structure of the Dox-Cis conjugate was characterized using Fourier Transform Infrared Spectroscopy (FTIR) and Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-Q-TOF/MS). The zeta potential and morphological parameters of the niosomal vesicles were determined through Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). In vitro assessments of cell viability and apoptosis were conducted on MUC-1 positive HeLa cells and MUC-1 negative U87 cells.
RESULTS
RESULTS
The findings confirmed the successful conjugation of Dox and Cis within the niosomes. The Nio/Dox-Cis/MUC-1 formulation demonstrated enhanced efficacy compared to the individual drugs and their unencapsulated combination in both cell lines. Notably, the Nio/Dox-Cis/MUC-1 formulation exhibited greater effectiveness on HeLa cells (38.503 ± 1.407) than on U87 cells (46.653 ± 1.297).
CONCLUSION
CONCLUSIONS
The study underscores the potential of the Dox-Cis conjugate as a promising strategy for cancer treatment, particularly through platforms that facilitate targeted drug delivery to cancer cells. This targeted approach could lead to more effective and personalized cancer therapies.
Substances chimiques
Doxorubicin
80168379AG
Mucin-1
0
Liposomes
0
Cisplatin
Q20Q21Q62J
Aptamers, Nucleotide
0
MUC1 protein, human
0
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70079Subventions
Organisme : Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Informations de copyright
© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.
Références
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12‐49.
Wei G, Wang Y, Yang G, Wang Y, Ju R. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics. 2021;11(13):6370‐6392.
Singh AP, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using nanomaterial‐based drug delivery vehicles. Signal Transduct Target Ther. 2019;4(1):33.
Senapati S, Thakur R, Verma SP, et al. Layered double hydroxides as effective carrier for anticancer drugs and tailoring of release rate through interlayer anions. J Control Release. 2016;224:186‐198.
Sesarman A, Muntean D, Abrudan B, et al. Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co‐encapsulation with curcumin. J Liposome Res. 2021;31(1):1‐10.
Hamishehkar H, Rahimpour Y, Kouhsoltani M. Niosomes as a propitious carrier for topical drug delivery. Expert Opin Drug Deliv. 2013;10(2):261‐272.
Khan DH, Bashir S, Correia A, et al. Utilization of green formulation technique and efficacy estimation on cell line studies for dual anticancer drug therapy with niosomes. Int J Pharm. 2019;572:118764.
Mirzaei‐Parsa MJ, Najafabadi MRH, Haeri A, et al. Preparation, characterization, and evaluation of the anticancer activity of artemether‐loaded nano‐niosomes against breast cancer. Breast Cancer. 2020;27(2):243‐251.
Jamalpoor Z, Ahmadi H, Heydari M, Abdouss M, Rahdar A, Díez‐Pascual AM. Chitosan based niosomal hydrogel with polyethylene glycol and halloysite nanotubes for curcumin delivery. J Mol Liq. 2024;401:124640.
Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181‐202.
Zhu G, Chen X. Aptamer‐based targeted therapy. Adv Drug Deliv Rev. 2018;134:65‐78.
Chen W, Zhang Z, Zhang S, Zhu P, Ko JKS, Yung KKL. Muc1: structure, function, and clinic application in epithelial cancers. Int J Mol Sci. 2021;22(12):6567.
Dhar P, McAuley J. The role of the cell surface mucin MUC1 as a barrier to infection and regulator of inflammation. Front Cell Infect Microbiol. 2019;24(9):117.
Chen X, Sandrine IK, Yang M, Tu J, Yuan X. MUC1 and MUC16: critical for immune modulation in cancer therapeutics. Front Immunol. 2024;15:1356913.
Lee DH, Choi S, Park Y, Jin HS. Mucin1 and Mucin16: therapeutic targets for cancer therapy. Pharmaceuticals. 2021;14(10):1053.
Kufe DW. MUC1‐C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013;32(9):1073‐1081.
Ma L, Kohli M, Smith A. Nanoparticles for combination drug therapy. ACS Nano. 2013;7(11):9518‐9525.
Correia AS, Gärtner F, Vale N. Drug combination and repurposing for cancer therapy: the example of breast cancer. Heliyon. 2021;7(1):e05948.
van der Zanden SY, Qiao X, Neefjes J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J. 2021;288(21):6095‐6111.
Liu B, Zhang X, Li C, et al. Magnetically targeted delivery of DOX loaded Cu9 S5 @mSiO2 @Fe3 O4 ‐PEG nanocomposites for combined MR imaging and chemo/photothermal synergistic therapy. Nanoscale. 2016;8(25):12560‐12569.
Johnstone TC, Suntharalingam K, Lippard SJ. Third row transition metals for the treatment of cancer. Philos Trans A Math Phys Eng Sci. 2015;373(2037):20140185.
Li K, Li J, Li Z, Men L, Zuo H, Gong X. Cisplatin‐based combination therapies: their efficacy with a focus on ginsenosides co‐administration. Pharmacol Res. 2024;203:107175.
Dasari S, Bernard TP. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364‐378.
Guo XL, Kang XX, Wang YQ, et al. Co‐delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy. Acta Biomater. 2019;15(84):367‐377.
Iram S, Zahera M, Khan S, et al. Gold nanoconjugates reinforce the potency of conjugated cisplatin and doxorubicin. Colloids Surf B Biointerfaces. 2017;160:254‐264.
Jin Y, Wang Y, Liu X, et al. Synergistic combination chemotherapy of lung cancer: cisplatin and doxorubicin conjugated prodrug loaded, glutathione and pH sensitive nanocarriers. Drug Des Devel Ther. 2020;14:5205‐5215.
Wang Y, Qian J, Yang M, et al. Doxorubicin/cisplatin co‐loaded hyaluronic acid/chitosan‐based nanoparticles for in vitro synergistic combination chemotherapy of breast cancer. Carbohydr Polym. 2019;225:115206.
Geyik C, Guler E, Gumus ZP, et al. Bioconjugation and applications of amino functional fluorescence polymers. Macromol Biosci. 2017;17(3): 1600232‐1600243.
Liu J, Jiang T, Li C, et al. Bioconjugated carbon dots for delivery of si Tnfα to enhance Chondrogenesis of mesenchymal stem cells by suppression of inflammation. Stem Cells Transl Med. 2019;8(7):724‐736.
Ag Seleci D, Seleci M, Stahl F, Scheper T. Tumor homing and penetrating peptide‐conjugated niosomes as multi‐drug carriers for tumor‐targeted drug delivery. RSC Adv. 2017;7(53):33378‐33384.
Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA‐451 in resistance of the MCF‐7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008;7(7):2152‐2159.
Barlas FB, Celikbas E, Arslan M, Timur S, Yagci Y. Gold nanoparticle conjugated poly(p‐phenylene‐β‐cyclodextrin)‐ graft ‐poly(ethylene glycol) for theranostic applications. J Appl Polym Sci. 2019;136(12):47250.
Mokhtari RB, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022‐38043.
Wang Y, Lina L, Xu L, et al. Arctigenin enhances the sensitivity of cisplatin resistant colorectal cancer cell by activating autophagy. Biochem Biophys Res Commun. 2019;520(1):20‐26.
Li L, Liao L, Ding Y, Zeng H. Dithizone‐etched CdTe nanoparticles‐based fluorescence sensor for the off–on detection of cadmium ion in aqueous media. RSC Adv. 2017;7(17):10361‐10368.
Razali MAA, Sanusi N, Ismail H, Othman N, Ariffin A. Application of response surface methodology (RSM) for optimization of cassava starch grafted polyDADMAC synthesis for cationic properties. Starch. 2012;64(12):935‐943.
Yi C, Qi S, Zhang D, Yang M. Covalent conjugation of multi‐walled carbon nanotubes with proteins. Methods Mol Biol. 2010;625:9‐17.
Demir B, Barlas FB, Gumus ZP, Unak P, Timur S. Theranostic niosomes as a promising tool for combined therapy and diagnosis: “all‐in‐one” approach. ACS Appl Nano Mater. 2018;1(6):2827‐2835.
Tlili A, Abdelghani A, Hleli S, Maaref M. Electrical characterization of a thiol SAM on gold as a first step for the fabrication of immunosensors based on a quartz crystal microbalance. Sensors. 2004;4(6):105‐114.
Guimarães D, Cavaco‐Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021;601:120571.
Sheikholeslami B, Lam NW, Dua K, Haghi M. Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate. Life Sci. 2022;300:120574.
Hajizadeh MR, Parvaz N, Barani M, et al. Diosgenin‐loaded niosome as an effective phytochemical nanocarrier: physicochemical characterization, loading efficiency, and cytotoxicity assay. Daru. 2019;27(1):329‐339.
Liang J, Zhang Z, Zhao H, et al. Simple and rapid monitoring of doxorubicin using streptavidin‐modified microparticle‐based time‐resolved fluorescence immunoassay. RSC Adv. 2018;8(28):15621‐15631.
Qin YT, Peng H, He XW, Li WY, Zhang YK. Highly effective drug delivery and cell imaging using fluorescent double‐imprinted nanoparticles by targeting recognition of the epitope of membrane protein. Anal Chem. 2019;91(20):12696‐12703.
Wang HY, Cao PP, He ZY, et al. Targeted imaging and targeted therapy of breast cancer cells via fluorescent double template‐imprinted polymer coated silicon nanoparticles by an epitope approach. Nanoscale. 2019;11(36):17018‐17030.
Luk CK, Tannock IF. Flow Cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. JNCI. 1989;81(1):55‐59.
Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release. 2004;96(2):273‐283.
Nakayama T, Otsuka S, Kobayashi T, et al. Dormant cancer cells accumulate high protoporphyrin IX levels and are sensitive to 5‐aminolevulinic acid‐based photodynamic therapy. Sci Rep. 2016;6(1):36478.
Xu S, Olenyuk BZ, Okamoto CT, Hamm‐Alvarez SF. Targeting receptor‐mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev. 2013;65(1):121‐138.
Yilmaz G, Demir B, Timur S, Becer CR. Poly(methacrylic acid)‐coated gold nanoparticles: functional platforms for theranostic applications. Biomacromolecules. 2016;17(9):2901‐2911.
Seleci DA, Seleci M, Jochums A, Walter JG, Stahl F, Scheper T. Aptamer mediated niosomal drug delivery. RSC Adv. 2016;6(91):87910‐87918.
Shao W, Liu X, Sun G, Hu XY, Zhu JJ, Wang L. Construction of drug–drug conjugate supramolecular nanocarriers based on water‐soluble pillar[6]arene for combination chemotherapy. Chem Commun. 2018;54(68):9462‐9465.
Muthumanickam S, Ramachandran B, Jeyakanthan J, Jegatheswaran S, Pandi B. Designing a novel drug–drug conjugate as a prodrug for breast cancer therapy: in silico insights. Mol Divers. 2024;4:9‐17.